Zydus Lifesciences jumps to Rs 1,125 on 29 June, up 2%, after extending its Sterling Biotech API acquisition deadline to 30 September 2026.

Active Pharmaceutical Ingredients are the core medicinal compounds in drug formulations.

For Zydus Lifesciences, acquiring this business supports its vertical integration strategy, allowing it to manufacture raw materials in-house and improve supply chain control and cost efficiency.

The transaction, initially expected to conclude by December 2024, has faced multiple extensions as both companies work through standard procedural and regulatory requirements that must be satisfied before assets formally transfer.

The latest push to September 30, 2026, reflects the time needed to complete these steps.

Separately, Zydus received a warning letter from the USFDA in June 2026 regarding its Baddi facility in Himachal Pradesh. The company clarified that the letter resulted from a records request rather than an on-site inspection.

The observations relate to technical protocols for purified talc, and Zydus confirmed it does not expect this to affect current facility operations or supplies.

On the financials, Zydus reported strong consolidated FY26 performance, with revenue from operations at Rs 27,148.40 crore and an adjusted net profit of Rs 5,456.40 crore.

For Q4FY26, consolidated revenue from operations came in at Rs 7,587 crore with a net profit of Rs 1,272.50 crore.

Zydus Lifesciences closed at Rs 1,121.65 on BSE on 29 June, up 1.83% from the previous close of Rs 1,101.50.

Unlock profitable opportunities every day! Tradz by EquityPandit provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Tradz by EquityPandit and start winning now!